Pushing Boundaries in HER2 Therapy: The ENHERTU Revolution

Ajouter une nouvelle offre d'emploi Health

2025-07-28 11:25:03

ENHERTU (fam-trastuzumab deruxtecan) has emerged as a groundbreaking force in oncological therapeutics, fundamentally altering treatment landscapes for HER2-positive cancers. This cutting-edge antibody-drug conjugate, developed through collaborative innovation between Daiichi Sankyo and AstraZeneca, has achieved remarkable regulatory success with approvals encompassing breast cancer, gastric...

0 Commentaires 0 Parts 175 Vue 0 Aperçu